Clinical trials: Advanced or Metastatic CRC
Colorectal Cancer, Metastatic Colon Cancer
A Study to Investigate Ompenaclid Combined With FOLFIRI Plus Bevacizumab in Advanced/Metastatic Colorectal Cancer
The purpose of this study is to measure tumor response to treatment with ompenaclid (RGX-202-01) in patients with previously treated RAS mutant advanced or metastatic CRC.
- Trial name
- NCT05983367
- Testing
- Ompenaclid, Bevacizumab, FOLFIRI regimen
- Where
- 28 sites in Belgium, France and 1 more
- Volunteers
- 76 people
- Sponsor
- Inspirna, Inc.
Solid Cancers, BRCA Mutation
A PARG Inhibitor DAT-2645 Monotherapy in Patients with Advanced/Metastatic Solid Tumors Harboring BRCA1/2 Loss of Function Alterations And/or Other Defects in the DDR Pathway
The primary objective of the study is to evaluate the safety, tolerability, PK, PD, and prilimary efficacy of a PARG inhibitor DAT-2645 in patients with advanced/metastatic solid tumors harboring BRCA1/2 loss of function…
- Conditions
- Solid Cancers, BRCA Mutation, HRD Cancer, Breast Cancer
- Trial name
- NCT06614751
- Testing
- DAT-2645 tablet
- Where
- 2 sites in China
- Volunteers
- 112 people
- Sponsor
- Danatlas Pharmaceuticals Co., Ltd
Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum
Combination Chemotherapy and Bevacizumab in Treating Patients With Locally Advanced, Metastatic, or Recurrent Colorectal Cancer
Drugs used in chemotherapy, such as oxaliplatin, leucovorin, fluorouracil, and capecitabine, work in different ways to stop cancer cells from dividing so they stop growing or die.
- Conditions
- Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum, Recurrent Colon Cancer, Recurrent Rectal Cancer
- Trial name
- NCT00070122
- Testing
- oxaliplatin, leucovorin calcium, capecitabine
- Where
- United States
- Volunteers
- 2,200 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer, Colorectal Cancer
Denileukin Diftitox Followed by Vaccine Therapy in Treating Patients With Metastatic Cancer
RATIONALE: Combinations of biological substances in denileukin diftitox may be able to carry cancer-killing substances directly to the cancer cells.
- Conditions
- Breast Cancer, Colorectal Cancer, Lung Cancer, Pancreatic Cancer
- Trial name
- NCT00128622
- Testing
- denileukin diftitox, recombinant fowlpox-CEA(6D)/TRICOM vaccine, therapeutic autologous dendritic cells
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- H. Kim Lyerly
Solid Tumor
A Study of ASP3082 in Adults With Advanced Solid Tumors
This is an open-label study. This means that people in this study and clinic staff will know that people will receive ASP3082. The study aims to check how safe and well-tolerated ASP3082 is for people with advanced solid tumors…
- Trial name
- NCT05382559
- Testing
- Setidegrasib, Cetuximab, Leucovorin
- Where
- 68 sites in United States, China and 5 more
- Volunteers
- 681 people
- Sponsor
- Astellas Pharma Inc
BRAF V600 Colorectal Cancer
A Study of Select Drug Combinations in Adult Patients With Advanced/Metastatic BRAF V600 Colorectal Cancer
A phase Ib, open-label platform study of select drug combinations chosen in order to characterize safety and tolerability of each treatment arm tested and to identify recommended doses and regimens for future studies.
- Trial name
- NCT04294160
- Testing
- Dabrafenib, LTT462, Trametinib
- Where
- 18 sites in United States, Australia and 8 more
- Volunteers
- 122 people
- Sponsor
- Novartis Pharmaceuticals
Metastatic Colorectal Cancer
Triplet (FOLFOXIRI) vs. Doublet (FOLFOX or FOLFIRI) Regimen as a 1st Line Treatment in Metastatic Colorectal Carcinoma
This is a prospective randomized phase II trial was done in clinical oncology department at Kasr Alainy hospital, Cairo university (NEMROCK) to evaluate the role of intensification of chemotherapy in the first line for treatment…
- Trial name
- NCT05316818
- Testing
- FOLFOXIRI Protocol
- Where
- Egypt
- Volunteers
- 64 people
- Sponsor
- Kasr El Aini Hospital
Renal Cell Cancer, Melanoma
Study of PF-07263689 in Participants With Selected Advanced Solid Tumors
This is a first-in-human, Phase 1, open label, multicenter, multiple dose, dose escalation and expansion study intended to evaluate the safety, viral load kinetics and shedding, pharmacodynamic, and anti-tumor activity of…
- Conditions
- Renal Cell Cancer, Melanoma, Non-Small-Cell Lung Cancer, Hepatocellular Cancer
- Trial name
- NCT05061537
- Testing
- PF-07263689, Sasanlimab
- Where
- 3 sites in United States
- Volunteers
- 13 people
- Sponsor
- Pfizer
Locally Advanced or Metastatic KRAS G12C-mutated Non-small Cell Lung Cancer, Advanced Solid Tumors Harboring the KRAS G12C Mutation
Rollover Study for Participants Who Have Been Treated With and Are Continuing to Benefit From Opnurasib as a Single Agent or in Combination With Other Study Treatments
The purpose of this study is to allow continued access to opnurasib (JDQ443) to participants who are benefitting from treatment with opnurasib as a single agent or in combination with other study treatments in pre-defined…
- Trial name
- KontRASt-R (NCT07468071)
- Testing
- Opnurasib, TNO155, trametinib
- Where
- 21 sites in Belgium, Canada and 8 more
- Volunteers
- 25 people
- Sponsor
- Novartis Pharmaceuticals
Advanced/Metastatic Solid Tumors, Colorectal Cancer
A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors
This is a Phase 1/2 open-label, multi-center, multi-national study with an initial dose escalation part to determine the recommended Phase II dose (RP2D) of MCLA-158 single agent in patients with mCRC.
- Conditions
- Advanced/Metastatic Solid Tumors, Colorectal Cancer, Gastric Cancer, Gastroesophageal-junction Cancer
- Trial name
- NCT03526835
- Testing
- MCLA-158, MCLA-158 + Pembrolizumab, MCLA-158 + FOLFIRI
- Where
- 54 sites in United States, Belgium and 5 more
- Volunteers
- 560 people
- Sponsor
- Genmab
Colorectal Cancer
BMS-247550 in Treating Patients With Recurrent or Metastatic Colorectal Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of BMS-247550 in treating patients who have recurrent or…
- Trial name
- NCT00022477
- Testing
- BMS-247550
- Where
- 15 sites in United States
- Volunteers
- 24 people
- Sponsor
- University of Chicago
Solid Tumors, NSCLC
A Study of Telaglenastat (CB-839) in Combination With Palbociclib in Patients With Solid Tumors
This is a Phase 1b/2 study to determine the recommended phase 2 dose (RP2D), safety and tolerability, pharmacokinetics (PK) and clinical activity of the glutaminase inhibitor telaglenestat (CB-839) with the CDK4/6 Inhibitor…
- Conditions
- Solid Tumors, NSCLC, CRC, KRAS Gene Mutation
- Trial name
- NCT03965845
- Testing
- Telaglenestat (CB-839), Palbociclib Oral Capsule or Tablet [Ibrance]
- Where
- 10 sites in United States
- Volunteers
- 53 people
- Sponsor
- Calithera Biosciences, Inc
Colorectal Cancer, Lung Cancer
QUILT-3.038: Active Immunotherapy CEA Vaccine in Patients With Malignancies Expressing CEA
The purpose of this study is to find out what effects (good and bad) that a cancer vaccine has on you and your cancer. The cancer vaccine is called Ad5 [E1-, E2b-]-CEA(6D)or ETBX-011 and is made by Etubics.
- Conditions
- Colorectal Cancer, Lung Cancer, Breast Cancer, Prostate Cancer
- Trial name
- NCT01147965
- Testing
- Ad5 CEA Vaccine
- Where
- 2 sites in United States
- Volunteers
- 43 people
- Sponsor
- NantCell, Inc.
Recurrent Colon Cancer, Recurrent Rectal Cancer
GTI-2040, Oxaliplatin, and Capecitabine in Treating Patients With Locally Advanced or Metastatic Colorectal Cancer or Other Solid Tumors
This phase I trial is studying the side effects and best dose of capecitabine when given together with GTI-2040 and oxaliplatin in treating patients with locally advanced or metastatic colorectal cancer or other solid tumors.
- Conditions
- Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage IIIC Colon Cancer, Stage IIIC Rectal Cancer
- Trial name
- NCT00084643
- Testing
- GTI-2040, oxaliplatin, capecitabine
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- National Cancer Institute (NCI)
Colorectal Cancer
Xeloda or UFT (Tegafur-uracil) With Folinic Acid in Advanced or Metastatic Colorectal Cancer
The scope of the trial is to determine the preference of patients, after randomization and cross-over, for one of the two treatments. Another objective of the trial is to assess and compare the safety of each treatment.
- Trial name
- COLOCROSS (NCT00905047)
- Testing
- XELODA, TEGAFUR URACIL - FOLINIC ACID
- Where
- 13 sites in France
- Volunteers
- 89 people
- Sponsor
- Centre Oscar Lambret
Colorectal Cancer, Head and Neck Cancer
Combination Study of Urelumab and Cetuximab in Patients With Advanced/Metastatic Colorectal Cancer or Advanced/Metastatic Head and Neck Cancer
The purpose of the study is to determine the safety, tolerability and maximum tolerated dose of Urelumab in combination with Cetuximab in patients with Advanced/Metastatic Colorectal Cancer or Advanced/Metastatic Squamous Cell…
- Trial name
- NCT02110082
- Testing
- Urelumab, Cetuximab
- Where
- 7 sites in United States
- Volunteers
- 66 people
- Sponsor
- Bristol-Myers Squibb
Cancer, Colon Cancer
PAVES: Pegfilgrastim Anti-vascular Endothelial Growth Factor (VEGF) Evaluation Study
This is a phase 3, randomized, double-blind, placebo-controlled multi-center study evaluating the efficacy of pegfilgrastim to reduce the incidence of febrile neutropenia (FN) in patients with newly diagnosed, locally-advanced or…
- Conditions
- Cancer, Colon Cancer, Colorectal Cancer, Fever
- Trial name
- NCT00911170
- Testing
- Pegfilgrastim, Bevacizumab, Standard Chemotherapy
- Where
- 154 sites in United States, Australia and 15 more
- Volunteers
- 847 people
- Sponsor
- Amgen
Colorectal Cancer, Liver Metastasis
Surgery Plus Sulindac or Surgery Alone for Advanced Colorectal Cancer
Background: Some types of inflammation may increase the risk of cancers in the intestinal track. Because of this possibility, anti-inflammatory drugs may be able to prevent tumor growth and spread.
- Conditions
- Colorectal Cancer, Liver Metastasis, Colorectal Adenocarcinoma
- Trial name
- NCT01856322
- Testing
- Sulindac, Validate assays and shipping methods
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- National Cancer Institute (NCI)
Colorectal Cancer
Dual Epidermal Growth Factor Receptor Inhibition With Erlotinib and Panitumumab With or Without Chemotherapy for Advanced Colorectal Cancer
RATIONALE: Erlotinib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as panitumumab, can block tumor growth in different ways.
- Trial name
- NCT00940316
- Testing
- panitumumab, erlotinib hydrochloride, irinotecan hydrochloride
- Where
- 10 sites in United States
- Volunteers
- 28 people
- Sponsor
- Northwestern University
Metastatic Solid Tumors
A Study of ERAS-0015 in Patients With Advanced or Metastatic Solid Tumors
The main purpose of the study is to assess whether the study drug, ERAS-0015, is safe and tolerable when administered to patients with advanced or metastatic solid tumors with certain RAS mutations.
- Trial name
- AURORAS-1 (NCT06983743)
- Testing
- ERAS-0015, ERAS-0015 in combination
- Where
- 9 sites in United States
- Volunteers
- 600 people
- Sponsor
- Erasca, Inc.